# Koneksa Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/koneksa-health

- Industry: Healthcare IT
- Headquarters: New York, US
- Website: www.koneksahealth.com
- Total disclosed funding: $60M
- Latest round: Series C (Dec 21, 2021)
- Investors on record: 9

## About

Koneksa Health Inc. is a digital health company focused on developing innovative solutions for remote data collection in clinical trials, specializing in digital biomarkers that support drug development processes.Founded in 2015, Koneksa Health Inc. is based in New York, US. The company focuses on creating digital biomarkers to improve clinical trial data collection. Most recently, Koneksa completed a Series C funding round in June 2022, raising USD 44.47 mn, led by Matrix Capital Management, with participation from several notable investors including McKesson Ventures and Merck Global Health Innovation Fund. The total amount raised to date is USD 44.47 mn, with a current valuation of USD 208.40 mn. Chris Benko serves as CEO, bringing significant experience in the healthcare technology space.Koneksa specializes in the development, testing, and validation of digital biomarkers, offering a comprehensive suite of solutions designed to enhance remote data collection in clinical trials. Their core offerings include a cloud-based Software-as-a-Service (SaaS) platform that allows real-time data aggregation from multiple endpoints, facilitating immediate access to insights that drive decision-making in drug development. Koneksa's services are tailored to meet the specific needs of drug developers, regulators, and health authorities across various therapeutic areas including neuroscience, oncology, and respiratory diseases. They serve a diverse clientele comprising pharmaceutical companies, biotechnology firms, and research institutions globally, particularly in North America and Europe, enabling them to optimize clinical trial designs and accelerate the development of effective treatments.Koneksa generates revenue primarily through partnerships and subscription models. Clients engage Koneksa's services on a contractual basis, which may involve per-trial fees or ongoing subscriptions for access to their SaaS platform and associated digital biomarker technologies. The structure of these transactions is typically B2B, where Koneksa collaborates closely with drug developers to implement their digital health solutions. This enables clients to utilize advanced algorithms and state-of-the-art measurement devices, enhancing the quality and frequency of data collected during trials. While specific pricing plans for individual services may vary based on the scope and complexity of the engagement, Koneksa’s flagship offerings are integral to their clients' research initiatives, providing vital support in the clinical trial process.Following a funding round completed on June 16, 2022, Koneksa Health Inc. plans to utilize the undisclosed amount received from The Michael J. Fox Foundation to evaluate speech symptoms in Parkinson's disease. The company aims to design and launch new products that enhance their digital biomarker offerings, although specific release dates have yet to be disclosed. Koneksa is also looking to expand its presence in additional international markets, with a focus on enhancing partnerships in Europe and Asia by the end of 2023.

## Funding rounds

- Series C, Dec 21, 2021, $44M — Spring Mountain Capital, Merck Global Health Innovation Fund, Takeda Ventures, Velocity Capital, Novartis International AG, Matrix Capital Management, Waterline Ventures, McKesson Ventures
- Series B, Sep 28, 2020, $16M — Spring Mountain Capital, Merck Global Health Innovation Fund, Novartis International AG, Waterline Ventures, McKesson Ventures, MBX Capital

## Investors

- Spring Mountain Capital (https://capitalatlas.ai/funds/spring-mountain-capital) — Series B, Series C
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series B, Series C
- Novartis International AG — Series B, Series C
- Waterline Ventures (https://capitalatlas.ai/funds/waterline-ventures) — Series B, Series C
- McKesson Ventures (https://capitalatlas.ai/funds/mckesson-ventures) — Series B, Series C
- MBX Capital (https://capitalatlas.ai/funds/mbx-capital) — Series B
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series C
- Velocity Capital (https://capitalatlas.ai/funds/velocity-capital) — Series C
- Matrix Capital Management — Series C